Type de Publication Article
    Titre Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013
    Auteurs Brouard C. | Pillonel J. | Sogni P. | Chollet A. | Lazarus J. V. | Pascal X. | Barin F. | Jauffret-Roustide M.
    Revue Epidemiology and Infection
    Résumé SUMMARY People who use drugs (PWUD) are a key population for hepatitis B virus (HBV) vaccination and screening. We aimed to estimate the seroprevalence of HBs antigen (HBsAg) and self-reported HBV vaccination history in French PWUD attending harm reduction centres using data from the ANRS-Coquelicot multicentre survey conducted in 2011–2013 in 1718 PWUD. Self-fingerprick blood samples were collected on dried blood spots to detect the presence of HBsAg. HBsAg seroprevalence was estimated at 1·4% [95% confidence interval (CI) 0·8–2·5]. It varied between PWUD born in high (7·6%, 95% CI 2·7–19·1), moderate (2·2%, 95% CI 0·8–5·7) and low (0·7%, 95% CI 0·3–1·5) endemic zones. Factors independently associated with HBsAg carriage were being born in a moderate or high endemic zone or reporting precarious housing. Self-reported HBV vaccination history varied from 47·4% in high endemic zones, to 59·3% and 62·6% for moderate and low endemic zones, respectively. Our results suggest that drug use plays a small and substantial role, respectively, in HBsAg carriage in PWUD born in high/moderate and low endemic zones.
    Pages 1259-1269
    Volume 145
    Numéro 6
    Mots clés Estimating | France | hepatitis B | people who use drugs (PWUD) | prevalence of disease | vaccination (immunization)
    Année 2017
    Editeur Cambridge University Press
    Url https://www.cambridge.org/core/article/hepatitis-b
    Electronic resource num 10.1017/S0950268816003137
    ISBN 0950-2688

    EN POURSUIVANT VOTRE NAVIGATION SUR CE SITE, VOUS ACCEPTEZ L’UTILISATION DE COOKIES OU AUTRES TRACEURS AFIN DE RÉALISER DES STATISTIQUES DE VISITES.